Farmácia/Notícias da Indústria
OMS | Desigualdade vacinal prejudica a recuperação econômica global.
23 Jul, 2021 | 10:19hComunicado de imprensa: Vaccine inequity undermining global economic recovery – World Health Organization
Painel: Global Dashboard for Vaccine Equity
Comentários: Urgent need for COVID-19 vaccine equity – University of Oxford E COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Comentário no Twitter (fio – clique para saber mais)
COVID-19 vaccine inequity is undermining 🌍 economic recovery. 🆕WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Opinião | Tocilizumabe no tratamento da COVID-19: quem se beneficia e como? – Os pesquisadores sugerem que inibidores de IL-6 talvez devam ser ministrados somente a pacientes com altos níveis de IL-6.
23 Jul, 2021 | 10:18hTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Relacionado: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. E M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. E RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes E Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. E M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Perspectiva | “Challenge Trials” com o SARS-CoV-2 (quando pessoas saudáveis são expostas deliberadamente ao virus, para fins de pesquisa) – Estabelecendo um modelo durante uma pandemia em evolução.
23 Jul, 2021 | 10:17hRelacionado: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o tema) E Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
CDC lança novas diretrizes para o tratamento de infecções sexualmente transmissíveis.
23 Jul, 2021 | 10:13hTabela de conteúdo: Sexually Transmitted Infections Treatment Guidelines, 2021
Relacionado (recém-lançado): WHO Guidelines for the management of symptomatic sexually transmitted infections.
Comentário no Twitter (fio – clique para saber mais)
Here's my greatest hits from today’s new @CDCSTD #STI Treatment Guidelines: a 🧵
1)#STI guidelines instead of #STD!
2)Expedited Partner Therapy: not just for “heterosexuals” 👏
3)#HepatitisC: screen all pregnant people
4)Rectal/throat GC/CT: consider for non-MSM like teens 👏 pic.twitter.com/gfEhrWpMKA— Ina Park (@InaParkMD) July 22, 2021
Estudo randomizado | Dolutegravir ou darunavir em combinação com zidovudina ou tenofovir no tratamento do HIV.
23 Jul, 2021 | 10:02hDolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Dolutegravir Confirmed as Effective Second-Line HIV Therapy; Recycling Tenofovir Noninferior to Zidovudine – Medscape (necessário cadastro gratuito)
Estudo mostra que vacinas da AstraZeneca e da Pfizer são eficazes contra a variante Delta, mas são necessárias as duas doses.
22 Jul, 2021 | 13:08hComentários: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes E Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Relacionado: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. E Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. E Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Comentário no Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
Estudo randomizado | Dapaglifozina em pacientes com fatores de risco cardiometabólico hospitalizados com COVID-19 – é segura, mas não traz uma redução estatisticamente significante no risco de morte ou outros desfechos.
22 Jul, 2021 | 13:06hComentário: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
Crianças devem tomar vacina contra COVID? O que diz a ciência.
22 Jul, 2021 | 13:05hShould children get COVID vaccines? What the science says – Nature
Análise mostra que os benefícios da vacinação contra COVID-19 pesam mais que os riscos de raros casos de miocardite.
22 Jul, 2021 | 13:04hComunicado de imprensa: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association
Estudo original: Myocarditis with COVID-19 mRNA Vaccines – Circulation
Comentário: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD
Comentário no Twitter
Just published ahead of print- Myocarditis with Covid mRNA Vaccines https://t.co/mc2yrr5pDV Mechanisms, benefit of COVID-19 mRNA vaccination over low risk, management strategies – review of all myocarditis cases published to date, CDC&other reports @PeterHotez @ishannovation
— BiykemBozkurt (@BiykemB) July 20, 2021